Object of study: patients with chronic obstructive pulmonary disease who volunteered for treatment with the Roncoleukin drug and allergen-specific immunotherapy in patients with COPD with sensitization to Alternaria alternata. The purpose of the study was to determine and investigate the effectiveness of the use of a non-specific immunocorrector Roncoleukin (a recombinant form of interleukin-2) and specific immunotherapy in the correction of immune disorders that accompany the development and progression of COPD in patients with sensitization to fungi and bacterial allergens. Methods of research: general clinical, X-ray, immunological (study of phagocytic, humoral and cellular immunity, cytokine content), immunofluorescence (determining the content of antibodies to mold antigens, yeast fungi, and bacterial allergens), as well as molecular allergic diagnosis (determination of IgE antibodies to major Alt a1 Alternaria alternata, and SEA, SEВ, Staphylococcus Aureus enterotoxins, mathematical and statistical research methods. Equipment: Hematological analyzer "Abacus Junior B" (Austria) Yu luminescent microscope "Olympus" СХ 41 (Japan), Microlab spirograph, flow cathometer FACS Calibur ("Becton Diskinson, USA), ImmunoCAP analyzer (manufacturer Phadia, Sweden). In the dissertation for the first time it was shown that in 48,0% of patients with COPD II degree and 52,3% of patients with COPD III degree of severity there is a sensitization to fungal and bacterial allergens. The research has proved the effectiveness of using a non-specific immune modulator Roncoleukin and ACIT in the correction of immune disorders observed in patients with COPD II and III severity levels with sensitization to fungi and bacterial allergens. ACTH in COPD with high IgE up to Alternaria Alternata was conducted for the first time. It has been shown for the first time that these patients have the ability to develop a complete T cell immune response by suppressing the production of IL-2 and INFγ, expression on CD4 + -cells of CD28, violation of the ratio of Th1 / Th2 cells, and a decrease in the proliferative capacity of T-lymphocytes. It has been proved that patients with COPD are suppressed both local and general immunity. It has been shown that application of Roncoleukin in the complex therapy of patients with COPD can increase the proliferative capacity of T lymphocytes, restore the ratio of Th1 / Th2 cells, increase the phagocytic activity of cells, decrease the level of CIC in the blood, increase the secretion of bronchial sIgA in serum mIgA. Under the influence of Roncoleukin in patients with COPD, blood levels of proinflammatory cytokines (IL-1β, FNPα) are reduced and the balance of pro- and anti-inflammatory cytokines is restored, IL-2 production is increased. The use of ACIT in patients with COPD leads to desensitization and a decrease in the level of general and specific IgE. Application Roncoleukin and ACIT in complex therapy positively affects the clinical course of the disease, prevents the risks of aggravation of the disease and its progression. In patients, there is a significant decrease in the frequency of such symptoms as shortness of breath, cough and the amount of sputum. Degree of implementation: 5 acts of implementation. Sphere (industry) of use: health protection (medicine: immunology, allergy, infectious diseases).
